These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26702901)

  • 1. Toll-like receptors mediating vascular malfunction: Lessons from receptor subtypes.
    Wang Y; Song E; Bai B; Vanhoutte PM
    Pharmacol Ther; 2016 Feb; 158():91-100. PubMed ID: 26702901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms.
    Loppnow H; Werdan K; Buerke M
    Innate Immun; 2008 Apr; 14(2):63-87. PubMed ID: 18713724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like Receptors in the Vascular System: Sensing the Dangers Within.
    Goulopoulou S; McCarthy CG; Webb RC
    Pharmacol Rev; 2016 Jan; 68(1):142-67. PubMed ID: 26721702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research Progress of Mechanisms and Drug Therapy For Atherosclerosis on Toll-Like Receptor Pathway.
    Yin QY; Zhao B; Qiu YY; Fei YX; Hu YH; Li YM
    J Cardiovasc Pharmacol; 2019 Nov; 74(5):379-388. PubMed ID: 31730559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk of toll-like receptors signaling and Nrf2 pathway for regulation of inflammation.
    Mohan S; Gupta D
    Biomed Pharmacother; 2018 Dec; 108():1866-1878. PubMed ID: 30372892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic role of toll-like receptor modification in cardiovascular dysfunction.
    Navi A; Patel H; Shaw S; Baker D; Tsui J
    Vascul Pharmacol; 2013 Mar; 58(3):231-9. PubMed ID: 23070056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor signaling pathways and the evidence linking toll-like receptor signaling to cardiac ischemia/reperfusion injury.
    Wang Y; Abarbanell AM; Herrmann JL; Weil BR; Poynter J; Manukyan MC; Crisostomo PR; Meldrum DR
    Shock; 2010 Dec; 34(6):548-57. PubMed ID: 20458266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAGE and TLRs: relatives, friends or neighbours?
    Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
    Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple roles of Toll-like receptor signaling in atherosclerosis.
    Björkbacka H
    Curr Opin Lipidol; 2006 Oct; 17(5):527-33. PubMed ID: 16960501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway.
    Lang T; Lo C; Skinner N; Locarnini S; Visvanathan K; Mansell A
    J Hepatol; 2011 Oct; 55(4):762-9. PubMed ID: 21334391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics.
    Jin M; Fang J; Wang JJ; Shao X; Xu SW; Liu PQ; Ye WC; Liu ZP
    Acta Pharmacol Sin; 2023 Dec; 44(12):2358-2375. PubMed ID: 37550526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of endothelial function by Toll like receptors.
    Salvador B; Arranz A; Francisco S; Córdoba L; Punzón C; Llamas MÁ; Fresno M
    Pharmacol Res; 2016 Jun; 108():46-56. PubMed ID: 27073018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Damage-associated molecular pattern activated Toll-like receptor 4 signalling modulates blood pressure in L-NAME-induced hypertension.
    Sollinger D; Eißler R; Lorenz S; Strand S; Chmielewski S; Aoqui C; Schmaderer C; Bluyssen H; Zicha J; Witzke O; Scherer E; Lutz J; Heemann U; Baumann M
    Cardiovasc Res; 2014 Mar; 101(3):464-72. PubMed ID: 24302630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of Toll-like receptor signaling pathways in innate immune responses.
    Qian C; Cao X
    Ann N Y Acad Sci; 2013 Apr; 1283():67-74. PubMed ID: 23163321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor signaling in parasitic infections.
    Ashour DS
    Expert Rev Clin Immunol; 2015 Jun; 11(6):771-80. PubMed ID: 25896399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in the development of Toll-like receptor (TLR) antagonists.
    Patra MC; Choi S
    Expert Opin Ther Pat; 2016 Jun; 26(6):719-30. PubMed ID: 27136061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
    Arsenault RJ; Kogut MH; He H
    Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets.
    Cole JE; Mitra AT; Monaco C
    Expert Rev Cardiovasc Ther; 2010 Nov; 8(11):1619-35. PubMed ID: 21090937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis.
    Loppnow H; Buerke M; Werdan K; Rose-John S
    J Cell Mol Med; 2011 Mar; 15(3):484-500. PubMed ID: 21199323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.